Home/Filings/4/0001415889-25-011574
4//SEC Filing

Foley Todd 4

Accession 0001415889-25-011574

CIK 0001785530other

Filed

Apr 29, 8:00 PM ET

Accepted

Apr 30, 4:17 PM ET

Size

21.5 KB

Accession

0001415889-25-011574

Insider Transaction Report

Form 4
Period: 2025-03-27
Transactions
  • Exercise of In-Money

    Warrant (Right to Buy)

    2025-03-274,0150 total(indirect: See Footnote)
    Exercise: $0.09Exp: 2025-04-09Common Stock (4,015 underlying)
  • Exercise of In-Money

    Common Stock

    2025-03-27$0.09/sh+22,758$2,0483,210,756 total(indirect: See Footnote)
  • Sale

    Common Stock

    2025-03-27$1.05/sh1,963$2,0613,208,793 total(indirect: See Footnote)
  • Exercise of In-Money

    Warrant (Right to Buy)

    2025-03-2718,7430 total(indirect: See Footnote)
    Exercise: $0.09Exp: 2025-08-13Common Stock (18,743 underlying)
Transactions
  • Exercise of In-Money

    Common Stock

    2025-03-27$0.09/sh+22,758$2,0483,210,756 total(indirect: See Footnote)
  • Exercise of In-Money

    Warrant (Right to Buy)

    2025-03-274,0150 total(indirect: See Footnote)
    Exercise: $0.09Exp: 2025-04-09Common Stock (4,015 underlying)
  • Sale

    Common Stock

    2025-03-27$1.05/sh1,963$2,0613,208,793 total(indirect: See Footnote)
  • Exercise of In-Money

    Warrant (Right to Buy)

    2025-03-2718,7430 total(indirect: See Footnote)
    Exercise: $0.09Exp: 2025-08-13Common Stock (18,743 underlying)
Transactions
  • Sale

    Common Stock

    2025-03-27$1.05/sh1,963$2,0613,208,793 total(indirect: See Footnote)
  • Exercise of In-Money

    Warrant (Right to Buy)

    2025-03-2718,7430 total(indirect: See Footnote)
    Exercise: $0.09Exp: 2025-08-13Common Stock (18,743 underlying)
  • Exercise of In-Money

    Warrant (Right to Buy)

    2025-03-274,0150 total(indirect: See Footnote)
    Exercise: $0.09Exp: 2025-04-09Common Stock (4,015 underlying)
  • Exercise of In-Money

    Common Stock

    2025-03-27$0.09/sh+22,758$2,0483,210,756 total(indirect: See Footnote)
Foley Todd
10% Owner
Transactions
  • Exercise of In-Money

    Warrant (Right to Buy)

    2025-03-274,0150 total(indirect: See Footnote)
    Exercise: $0.09Exp: 2025-04-09Common Stock (4,015 underlying)
  • Sale

    Common Stock

    2025-03-27$1.05/sh1,963$2,0613,208,793 total(indirect: See Footnote)
  • Exercise of In-Money

    Warrant (Right to Buy)

    2025-03-2718,7430 total(indirect: See Footnote)
    Exercise: $0.09Exp: 2025-08-13Common Stock (18,743 underlying)
  • Exercise of In-Money

    Common Stock

    2025-03-27$0.09/sh+22,758$2,0483,210,756 total(indirect: See Footnote)
Transactions
  • Exercise of In-Money

    Common Stock

    2025-03-27$0.09/sh+22,758$2,0483,210,756 total(indirect: See Footnote)
  • Sale

    Common Stock

    2025-03-27$1.05/sh1,963$2,0613,208,793 total(indirect: See Footnote)
  • Exercise of In-Money

    Warrant (Right to Buy)

    2025-03-274,0150 total(indirect: See Footnote)
    Exercise: $0.09Exp: 2025-04-09Common Stock (4,015 underlying)
  • Exercise of In-Money

    Warrant (Right to Buy)

    2025-03-2718,7430 total(indirect: See Footnote)
    Exercise: $0.09Exp: 2025-08-13Common Stock (18,743 underlying)
Transactions
  • Exercise of In-Money

    Warrant (Right to Buy)

    2025-03-2718,7430 total(indirect: See Footnote)
    Exercise: $0.09Exp: 2025-08-13Common Stock (18,743 underlying)
  • Exercise of In-Money

    Common Stock

    2025-03-27$0.09/sh+22,758$2,0483,210,756 total(indirect: See Footnote)
  • Sale

    Common Stock

    2025-03-27$1.05/sh1,963$2,0613,208,793 total(indirect: See Footnote)
  • Exercise of In-Money

    Warrant (Right to Buy)

    2025-03-274,0150 total(indirect: See Footnote)
    Exercise: $0.09Exp: 2025-04-09Common Stock (4,015 underlying)
Footnotes (6)
  • [F1]On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 22,758 shares of the Company's Common Stock for $0.09 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 1,963 of the warrant shares to pay the exercise price and issuing the remaining 20,795 shares.
  • [F2]The shares are held as follows: 2,915,905 by MPM BioVentures 2014, L.P. ("BV 2014"), 194,486 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)") and 100,365 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014.Todd Foley is a Managing Director of BV LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
  • [F3]The shares are held as follows: 2,914,123 by BV 2014, 194,367 by MPM 2014(B) and 100,303 by AM BV2014. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
  • [F4]Immediately exercisable.
  • [F5]The warrants were held as follows: 3,647 by BV 2014, 243 by BV 2014(B) and 125 by AM BV 2014.
  • [F6]The warrants were held as follows: 17,023 by BV 2014, 1,135 by BV 2014(B) and 585 by AM BV 2014.

Issuer

Werewolf Therapeutics, Inc.

CIK 0001785530

Entity typeother

Related Parties

1
  • filerCIK 0001473930

Filing Metadata

Form type
4
Filed
Apr 29, 8:00 PM ET
Accepted
Apr 30, 4:17 PM ET
Size
21.5 KB